MFSD13A

Across TCGA pan-cancer cohorts, MFSD13A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MFSD13A data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MFSD13A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MFSD13A expression acts as an unfavorable survival marker.

CCRCC and LUAD are the cancer types where MFSD13A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.511	1.000	.005	14	view →
LUAD	DFS	Quartile	All	0.789	1.000	.006	13	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MFSD13A–CCRCC (DFS)

Open the CCRCC breakdown →